Olympus Expands Lung Cancer Diagnostics with Slim EBUS Bronchoscope…

Event summary

Olympus launched the BF-UCP190F peripheral EBUS bronchoscope in the U.S. on October 15, 2026, designed to reach deeper lung regions for lung cancer diagnosis.
The 5.9mm diameter bronchoscope enables sampling from segmental and sub-segmental airways, expanding beyond mediastinal lymph nodes.
EBUS-TBNA samples collected with the device are adequate for next-generation sequencing in 90.3% of cases, supporting personalized treatment planning.
The device integrates with Olympus' EVIS X1™ Endoscopy System and EU-ME3 Ultrasound Processor for comprehensive lung diagnostics.

The big picture

Olympus' launch of the BF-UCP190F bronchoscope underscores the growing emphasis on minimally invasive, high-precision diagnostic tools in lung cancer care. With lung cancer being the leading cause of cancer deaths in the U.S., early detection and accurate staging are critical. This device strengthens Olympus' position in the respiratory diagnostics market, particularly as it integrates with its existing imaging and ultrasound platforms. The strategic move aligns with broader industry trends toward personalized medicine and real-time diagnostic capabilities.

What we're watching

Diagnostic Reach: How the extended reach of the BF-UCP190F will impact early detection and staging of lung cancer.
Market Adoption: Whether pulmonologists will widely adopt the new device given its precision and compatibility with existing needles.
Competitive Positioning: The pace at which Olympus can differentiate itself in the lung cancer diagnostics market with this innovation.